Lantern Pharma Inc.
The research page contains a warning that has not been mapped to a supported model interpretation. The company research remains available, but the complete score is withheld until the warning is reviewed.
LTRN · Price history
Price at last available close
$0.64
−$0.45 (-41.28%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Lantern Pharma Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked.
How they make money
Lantern Pharma is a clinical-stage biopharmaceutical company that utilizes its proprietary RADR artificial intelligence and machine learning platform to identify and develop oncology drug candidates. The company aims to generate revenue through the future commercialization of its drug candidates, potential licensing agreements, and subscription or usage-based fees from its AI platforms like withZeta.ai.
Products & services
The company develops a portfolio of AI-driven oncology drug candidates, including LP-184, LP-284, and LP-300, and operates AI platforms RADR and withZeta.ai for drug discovery and development.
Brands & revenue mix
Proprietary AI and machine learning platform for oncology drug discovery.
Separate brand revenue is not available in this research.Source
AI platform designed for subscription and usage-based licensing models.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) — The company relies on various unnamed third-party contract research organizations to conduct preclinical and clinical trials.Source
- Contract Development and Manufacturing Organizations (CDMOs) — The company relies on unnamed third-party contract development and manufacturing organizations for the production of its drug candidates.Source
Strengths
Sources
Company-specific research
Questions worth answering for LTRN
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can LTRN fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is LTRN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for LTRN to reach sustainable profitability?
- •What future growth or profitability would be needed to justify LTRN's current valuation?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of LTRN's score?
Essential Investment Snapshot
Market Cap
$9.6M
P/E Ratio
-0.6
EPS
$-1.62
52-Week High
$4.70
52-Week Low
$0.84
Beta
2.30
Shares Outstanding
10.9M
Total Debt
$40K
Dividend
No current dividend
Liquidation Value / Share
$-0.30
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
High movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on LTRN.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary RADR AI platform for oncology drug discovery.
- +Experienced management team in drug development and AI.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and expectation of future losses.
- −Dependence on third-party manufacturers and clinical research organizations.
- −Uncertainty of clinical trial success and regulatory approval.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$0.64
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $4K | $0.00 | $0.00 | $175K | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | -$4K | $0.00 | $0.00 | -$175K | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $8.7M | $11.5M | $16.1M | $11.9M | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $6.8M | $6.5M | $6.1M | $6.0M | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $15.5M | $18.0M | $22.2M | $17.7M | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$18.6M | -$17.1M | -$20.8M | -$15.8M | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$15.5M | -$18.0M | -$22.2M | -$17.9M | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$18.7M | -$17.1M | -$20.8M | -$16.0M | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$18.7M | -$17.1M | -$20.8M | -$16.0M | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-1.62 | $-1.57 | $-1930.92 | $-1.47 | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 12.42M | 10.90M | 10.76M | 10.84M | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 12.42M | 10.90M | 10.76M | 10.84M | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.57
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-72.6%
Cash Change
+9.9%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included EPS growth, cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS increased 42.5%. Cash increased 9.9%. Total debt declined 72.6%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering
Rumor Mill · LTRN
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial